Fundz
Back to SEC Filings
10-KMEDIUM RiskSTABLE

ProPhase Labs, Inc.

Filed: Jun 1, 2026 CIK: 0000868278
View original filing on SEC.gov

AI Executive Summary

AI-powered analysis of 10-K filing content

ProPhase Labs is transitioning from COVID-19 testing to a diversified biotech company focused on genomics, diagnostics, and supplements. The company shows promise with its BE-Smart esophageal cancer test collaboration with Mayo Clinic, but remains in development stage with uncertain commercialization timeline and revenue generation.

Red Flags Detected (4)

BE-Smart test still requires further clinical testing before commercialization

Previous COVID-19 testing revenue stream appears to be winding down

Small reporting company with limited risk factor disclosures required

1 more red flag detected

Key Takeaways

Company owns exclusive rights to BE-Smart esophageal pre-cancer diagnostic test

Strong partnership with Mayo Clinic and mProbe for BE-Smart development

2 more takeaways

Filing Overview

Form TypeAnnual Report (10-K)
Filing DateJun 1, 2026
Risk LevelMEDIUM
TrendSTABLE
AI Confidence75%
Red Flags4

What This Means

Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.

View Full Filing on SEC.govBrowse More Filings